Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Neurocrine Bioscienc (NQ: NBIX ) 137.76 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Neurocrine Bioscienc < Previous 1 2 3 4 5 6 7 Next > 3 Red-Hot Biotech Rockets Blasting Off in 2024 April 24, 2024 The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits. Via InvestorPlace Topics Economy Exposures Economy Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder April 23, 2024 Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in... Via Benzinga No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win April 23, 2024 The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza. Via Investor's Business Daily Why NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase. April 11, 2024 Via Chartmill Where Neurocrine Biosciences Stands With Analysts April 10, 2024 Via Benzinga For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. April 10, 2024 Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. Via Chartmill NASDAQ:NBIX is not too expensive for the growth it is showing. March 20, 2024 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is showing decent growth, but is still valued reasonably. Via Chartmill Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. March 20, 2024 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. Via Chartmill Why Quality-Oriented Investors Should Consider NASDAQ:NBIX. March 15, 2024 Analyzing the Quality Characteristics of NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). Via Chartmill Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag. April 05, 2024 In a market where value is scarce, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) offers a refreshing opportunity with its solid fundamentals. Via Chartmill S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind March 23, 2024 DexCom, Blackstone and Royal Caribbean head this list of five stocks. Via Investor's Business Daily Topics Economy Stocks Exposures Interest Rates US Equities Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform March 19, 2024 Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term... Via Benzinga Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark March 18, 2024 On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. Via Investor's Business Daily AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base March 16, 2024 Three of the featured stocks are closing in on record highs. Via Investor's Business Daily Topics Artificial Intelligence Exposures Artificial Intelligence Decoding 8 Analyst Evaluations For Neurocrine Biosciences March 13, 2024 Via Benzinga Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock? February 28, 2024 Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation. Via Chartmill NASDAQ:NBIX is probably undervalued for the fundamentals it is displaying. March 14, 2024 When you look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. Via Chartmill In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences March 13, 2024 Via Benzinga 3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success March 06, 2024 With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector. Via InvestorPlace Amicus Therapeutics Stock Sees RS Rating Improve To 74 March 05, 2024 In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. Via Investor's Business Daily Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced. February 28, 2024 For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. Via Chartmill Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat February 27, 2024 Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. Via Investor's Business Daily Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views February 08, 2024 Via Benzinga Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark February 23, 2024 Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84. Via Investor's Business Daily Beam Therapeutics Stock Shows Healthy Relative Strength Improvement February 16, 2024 In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday. Via Investor's Business Daily Alkermes Stock Gets RS Rating Upgrade; Profits Surge February 15, 2024 In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday. Via Investor's Business Daily CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+ February 13, 2024 CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. Via Investor's Business Daily Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise February 12, 2024 Shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) climbed in early trading on Monday, after several analysts raised their forecasts. Via Benzinga Amicus Therapeutics Stock Sees Improved Relative Strength Rating February 09, 2024 In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. Via Investor's Business Daily Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review February 08, 2024 The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply. Via Investor's Business Daily Topics Artificial Intelligence Stocks Exposures Artificial Intelligence US Equities < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.